A5024207397- Inflammatory Bowel Disease
- Microscopic Colitis
- Celiac Disease Research and Management
- Eosinophilic Esophagitis
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Gastrointestinal Bleeding Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Platelet Disorders and Treatments
- Pregnancy and Medication Impact
- Liver Diseases and Immunity
- Autoimmune Bullous Skin Diseases
- Viral Infections and Immunology Research
- Reproductive System and Pregnancy
- Antimicrobial Resistance in Staphylococcus
Universidade Estadual Paulista (Unesp)
2022-2025
Abstract Background Vedolizumab (VDZ) is an α4β7 integrin antibody used to treat moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). We aimed assess the real-life long-term effectiveness safety of VDZ as a first- or second-line biological therapy identify predictors efficacy in large cohort patients with refractory difficult-to-treat UC. Methods This was multicenter, retrospective observational study including moderately-to-severely active UC who received for at least 12...
Abstract Background Ustekinumab (UST), an antibody targeting the p40 subunit of interleukin-12/23, has demonstrated efficacy in patients with Crohn’s disease (CD). However, comparative real-world data regarding positioning biologic therapies, particularly UST versus anti-tumour necrosis factor (TNF) agents, remain limited. This study aimed to compare effectiveness and safety anti-TNF agents biologic-naïve biologic-failure CD patients. Methods A multicentre retrospective cohort was conducted,...
Inflammatory bowel disease (IBD) affects young adults of reproductive age, and questions related to pregnancy breastfeeding are common in clinical practice. Most medications used treat IBD considered safe during pregnancy, except methotrexate small molecules such as tofacitinib. Despite few studies regarding vedolizumab (VDZ) safety, it appears be pregnancy. Therefore, this study aimed report the management ulcerative colitis pregnant patient refractory anti-tumor necrosis factor (TNF)...
Rationale: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by continuous inflammation of the colonic mucosa. Autoimmune hepatitis (AIH) a chronic liver hypergammaglobulinemia, circulating autoantibodies, interface hepatitis, and favorable response to immunosuppression. An association between IBD AIH uncommon, experts have suggested that in patients with overlapping AIH, anti-tumor necrosis factor agents can be used. Therefore, this study reports rare case patient...
Immune thrombocytopenic purpura (ITP) is characterized by the presence of autoantibodies against platelet membrane antigens, leading to immune-mediated destruction. ITP considered as a rare extraintestinal manifestation (EIM) ulcerative colitis (UC). This report aimed describe case UC associated with and review literature. A 49-year-old man was admitted our hospital severe acute which responsive treatment (hydrocortisone 300 mg/day). The patient discharged from prednisone 60 mg/day...
Abstract Background Vedolizumab (VDZ) and infliximab (IFX), are considered first-line agents in the treatment of moderate to severe Ulcerative Colitis (UC). However, there no head-to-head studies comparing relative effectiveness two agents, Real-world data on safety VDZ IFX UC lacking Brazilian population. We aimed compare Biologic-naïve patients. Methods conducted a multicenter retrospective cohort study, including patients with (Total Mayo score 6-12, an endoscopic subscore 2 or 3) who...